AN2 Therapeutics Director Readnour Sells 1,108 Shares

What Happened
Readnour Robin Shane, a member of AN2 Therapeutics' board, sold a total of 1,108 shares of ANTX stock on September 9, 2026 (523 shares and 585 shares). The reported sale prices were about $6.02 per share (weighted average range $6.02–$6.04 per F3), for combined proceeds of approximately $6,675. These were disposals (transaction code S) executed automatically under Rule 10b5-1 trading plans adopted April 23, 2026.

Key Details

• Transaction date: 2026-09-09 (reported in a Form 4 filed 2026-09-11; filing marked late).
• Shares sold: 523 and 585 (total 1,108).
• Price: reported ~ $6.02 per share; filing notes a weighted average range $6.02–$6.04 and offers to provide per-price breakdown on request (F3).
• Proceeds: roughly $3,151 and $3,524 respectively, total ≈ $6,675.
• Footnotes: sales were automatic under Rule 10b5-1 plans for MGC Venture Partners 2018, LP and MGC Venture Partners QP 2018, LP (F1, F2). Reporting person is a member/manager of related MGC entities and disclaims beneficial ownership except for pecuniary interest; shares are held directly by those MGC entities (F4–F6).
• Shares owned after the transaction: not specified in the excerpt of the filing.

Context
These were sales (routine disposals) executed under pre-established 10b5-1 plans, which are commonly used to avoid questions about timing. The reporter is affiliated with institutional entities (MGC 2018 LP / QP) rather than a simple personal open-market sale; the filing clarifies entity relationships and a disclaimer of direct beneficial ownership. Because this is a sale under a 10b5-1 plan, it should be viewed as a routine plan-driven transaction rather than a direct signal about company prospects.